Daniil Gataulin
Stock Analyst at Chardan Capital
(4.72)
# 123
Out of 5,172 analysts
130
Total ratings
58.97%
Success rate
38.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniil Gataulin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANNX Annexon | Maintains: Buy | $16 | $5.11 | +213.11% | 2 | Mar 20, 2026 | |
| CRVO CervoMed | Maintains: Buy | $15 → $21 | $4.02 | +422.39% | 9 | Mar 18, 2026 | |
| IRD Opus Genetics | Maintains: Buy | $9 → $11 | $4.39 | +150.57% | 4 | Mar 12, 2026 | |
| QURE uniQure | Maintains: Buy | $16 → $31 | $16.09 | +92.67% | 13 | Mar 9, 2026 | |
| OCGN Ocugen | Maintains: Buy | $7 | $2.04 | +243.14% | 16 | Mar 5, 2026 | |
| EYPT EyePoint | Maintains: Buy | $27 → $29 | $13.23 | +119.20% | 13 | Mar 4, 2026 | |
| OTLK Outlook Therapeutics | Maintains: Neutral | $1 | $0.35 | +184.82% | 12 | Feb 18, 2026 | |
| OCUL Ocular Therapeutix | Maintains: Buy | $21 | $8.18 | +156.72% | 5 | Feb 18, 2026 | |
| RGNX REGENXBIO | Maintains: Buy | $52 → $50 | $8.10 | +517.28% | 16 | Feb 10, 2026 | |
| KLRS Kalaris Therapeutics | Initiates: Buy | $19 | $6.56 | +189.63% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $61 | $23.50 | +159.57% | 7 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 | $22.25 | -37.08% | 4 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $5.50 | +81.82% | 3 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $7.20 | +386.11% | 7 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 | $24.86 | +105.15% | 9 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.07 | +273.83% | 8 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,200 | $3.98 | +55,176.38% | 1 | Mar 7, 2024 |
Annexon
Mar 20, 2026
Maintains: Buy
Price Target: $16
Current: $5.11
Upside: +213.11%
CervoMed
Mar 18, 2026
Maintains: Buy
Price Target: $15 → $21
Current: $4.02
Upside: +422.39%
Opus Genetics
Mar 12, 2026
Maintains: Buy
Price Target: $9 → $11
Current: $4.39
Upside: +150.57%
uniQure
Mar 9, 2026
Maintains: Buy
Price Target: $16 → $31
Current: $16.09
Upside: +92.67%
Ocugen
Mar 5, 2026
Maintains: Buy
Price Target: $7
Current: $2.04
Upside: +243.14%
EyePoint
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $29
Current: $13.23
Upside: +119.20%
Outlook Therapeutics
Feb 18, 2026
Maintains: Neutral
Price Target: $1
Current: $0.35
Upside: +184.82%
Ocular Therapeutix
Feb 18, 2026
Maintains: Buy
Price Target: $21
Current: $8.18
Upside: +156.72%
REGENXBIO
Feb 10, 2026
Maintains: Buy
Price Target: $52 → $50
Current: $8.10
Upside: +517.28%
Kalaris Therapeutics
Dec 23, 2025
Initiates: Buy
Price Target: $19
Current: $6.56
Upside: +189.63%
Nov 17, 2025
Maintains: Buy
Price Target: $61
Current: $23.50
Upside: +159.57%
Nov 17, 2025
Maintains: Neutral
Price Target: $14
Current: $22.25
Upside: -37.08%
Nov 14, 2025
Maintains: Buy
Price Target: $10
Current: $5.50
Upside: +81.82%
Nov 14, 2025
Maintains: Buy
Price Target: $35
Current: $7.20
Upside: +386.11%
Nov 11, 2025
Maintains: Buy
Price Target: $51
Current: $24.86
Upside: +105.15%
Aug 8, 2025
Maintains: Buy
Price Target: $4
Current: $1.07
Upside: +273.83%
Mar 7, 2024
Maintains: Buy
Price Target: $2,200
Current: $3.98
Upside: +55,176.38%